New antibody study could better treat Crohns and colitis

New crohns and colitis study

A new investigational is an effective treatment for patients who suffer from the inflammatory bowel diseases Crohn’s disease and colitis when other treatments fail, a study has found.

The international GEMINI studies, led by Western University’s Dr. Brian Feagan, found that the antibody vedolizumab is effective for patients with () and Crohn’s disease (CD), and may be a for patients whose current treatments are not working.

“This was really an important finding for patients who are failing these medications and are suffering from ,” Feagan told CTV News. “It’ll give them another option.”

UC and CD are two of the most common forms of inflammatory bowel disease, affecting more than four million people around the world. Symptoms of the diseases can include bleeding, , , and . has one of the highest rates of in the world.

Read more: New antibody could better treat Crohn’s and colitis: study

Leave a Reply